Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The conditional approval allows two U.S. sites to enroll up to five total patients. The FDA has also requested that the Company conduct additional device testing and address outstanding questions. Second Sight has 45 days to respond to FDA's requests.
Specialized droplets interact with bacteria and can be analyzed using a smartphone.
An updated clinical practice guideline from the American Academy of Otolaryngology-Head and Neck Surgery Foundation published today in Otolaryngology-Head and Neck Surgery provides evidence-based recommendations on diagnosis and treatment of earwax (cerumen impaction) as well as important patient information on the dos and don’ts of earwax and healthy ear care.